Preparations For Tests Of The Russian Vaccine In Brazil Will Begin Next Week
The technological Institute of the state of Parana (Tecpar) will apply next week to the Russian manufacturer of the coronavirus vaccine for technical documentation on the drug, without which it is impossible to start its testing and certification in the South American state. The head of the Civil office of the Governor of this southern state, Guto Silva, told TASS on Tuesday.
"We believe that after the signing of the framework agreement tomorrow, Tecpar will be able to prepare an appeal to the Russian authorities for the provision of protocols, after which we will be able to appeal to the regulator," the politician said in an interview with TASS. He also said that more detailed terms and stages of implementation of the framework document on scientific and technical cooperation, as well as issues of vaccine supply, access to appropriate Russian technology and the possibility of manufacturing the drug in Brazil will be discussed during tomorrow's online meeting of the Governor of Parana Ratino Junior with the head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev.
According to Silva, Tecpar has the appropriate scientific and production base for conducting laboratory tests of the Russian vaccine, and its ties with the Osvaldo Cruz research Association (Fiocruz) under the Brazilian Ministry of health will allow conducting research, including at the Federal level. "We are interested in becoming the center of distribution of this vaccine; our position is shared by the Federal government, which is important," he said.
Earlier on Tuesday, Brazilian media reported that the government of the state of Parana and RDIF are about to sign an agreement on testing and production of a Russian antiviral vaccine. After that, the national health surveillance Agency (Anvisa) reported that it had not received applications for testing and registration of the drug.
On August 11, Russia was the first in the world to register a coronavirus vaccine, called Sputnik V. The drug was developed By the National Research Center for Epidemiology and Microbiology named after N. F. Gamalei of the Ministry of Health of the Russian Federation and passed clinical trials in June - July. It is based on an already well-known platform, which has created several other vaccines.
According to the Ministry of health, the experience of using such drugs shows that they can give long - term immunity-up to two years. Kirill Dmitriev, head of The Russian direct investment Fund, said that Russia has already received applications from 20 countries for the supply of 1 billion doses of the vaccine.